Cytosorbents (NASDAQ:CTSO) Given “Neutral” Rating at HC Wainwright

Cytosorbents (NASDAQ:CTSO)‘s stock had its “neutral” rating restated by HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $1.00 target price on the medical research company’s stock. HC Wainwright’s target price would suggest a potential upside of 23.75% from the stock’s current price.

A number of other equities analysts also recently issued reports on the company. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research report on Friday, May 2nd. StockNews.com assumed coverage on Cytosorbents in a research report on Tuesday. They set a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Trading Down 7.1%

NASDAQ CTSO opened at $0.81 on Thursday. The company has a fifty day moving average of $1.00 and a 200 day moving average of $0.99. The company has a market capitalization of $50.60 million, a PE ratio of -2.24 and a beta of 1.17. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents has a 1 year low of $0.70 and a 1 year high of $1.61.

Cytosorbents (NASDAQ:CTSO) last posted its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The firm had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.01 million. Research analysts forecast that Cytosorbents will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Cytosorbents

Hedge funds and other institutional investors have recently made changes to their positions in the company. Avenir Corp lifted its holdings in Cytosorbents by 63.1% in the 1st quarter. Avenir Corp now owns 5,044,918 shares of the medical research company’s stock valued at $5,045,000 after purchasing an additional 1,950,972 shares in the last quarter. CM Management LLC raised its position in shares of Cytosorbents by 36.3% in the first quarter. CM Management LLC now owns 954,076 shares of the medical research company’s stock valued at $954,000 after buying an additional 254,076 shares during the last quarter. Skylands Capital LLC lifted its stake in shares of Cytosorbents by 7.9% in the first quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company’s stock worth $3,003,000 after buying an additional 221,080 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Cytosorbents during the fourth quarter worth about $99,000. Finally, Key Client Fiduciary Advisors LLC grew its stake in Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock valued at $78,000 after acquiring an additional 43,900 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.